Search

Your search keyword '"Boccadoro M."' showing total 133 results

Search Constraints

Start Over You searched for: Author "Boccadoro M." Remove constraint Author: "Boccadoro M." Journal leukemia Remove constraint Journal: leukemia
133 results on '"Boccadoro M."'

Search Results

1. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis

2. A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma

4. Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival

5. Circulating miRNA markers show promise as new prognosticators for multiple myeloma

7. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia

8. Lenalidomide−prednisone induction followed by lenalidomide−melphalan−prednisone consolidation and lenalidomide−prednisone maintenance in newly diagnosed elderly unfit myeloma patients

11. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

13. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)

14. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

17. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

19. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

20. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)

23. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

28. Lenalidomide — prednisone induction followed by lenalidomide — melphalan — prednisone consolidation and lenalidomide — prednisone maintenance in newly diagnosed elderly unfit myeloma patients

33. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network

34. Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma

35. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis

36. Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma

37. Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival

38. Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma

39. Extracellular vesicles as potential biomarkers of acute graft-vs-host disease

40. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders

41. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia

42. Lenalidomide−prednisone induction followed by lenalidomide−melphalan−prednisone consolidation and lenalidomide−prednisone maintenance in newly diagnosed elderly unfit myeloma patients

45. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia

46. Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.

47. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).

48. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network.

49. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN).

50. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias.

Catalog

Books, media, physical & digital resources